May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
LDL-Receptor Expression in Pterygia Neovascular Vessels
Author Affiliations & Notes
  • M.J. Lustig
    Ophthalmology, NYU Medical Center, New York, NY, United States
  • S. Doshi
    Ophthalmology, NYU Medical Center, New York, NY, United States
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1323. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M.J. Lustig, S. Doshi; LDL-Receptor Expression in Pterygia Neovascular Vessels . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1323.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Pterygia are a common cause of both chronic eye irritation as well as vision loss. Current surgical management of pterygia is disruptive to the conjunctiva, and recurrences are very common. Our research focuses on determining new ways to treat pterygia with verteporfin. Verteporfin is one of the treatments of choice for choroidal neovascularization in exudative age related macular degeneration (ARMD). Verteporfin complexes with low density lipoprotein (LDL), which is then bound to and endocytosed by neovascular vessels. The purpose of this study is to determine the presence of LDL-receptor on the endothelial cells of pterygium tissue, to ascertain whether verteporfin may be used to treat pterygium as a primary treatment. Method: Conjunctival neovascular tissue were obtained from patients undergoing pterygium excision. All samples were fixed in 2% paraformaldehyde for one hour and then stored in PBS at 4° C until immunofluorescent staining. Commercially obtained anti-LDL-receptor, control, and secondary fluorescent antibodies were used for staining all samples using standard immunofluorescent protocols. Results: The immunofluorescent staining patterns for LDL-receptor of pterygium are studied. Immunofluorescent staining patterns of LDL-receptor and control antibodies on neovascularized conjunctival tissue will be shown. Conclusion: Photodynamic therapy (PDT) using verteporfin has been widely applicable in its use for various neovascular disease processes. Since its approval for the treatment of exudative ARMD, verteporfin has been used experimentally for the treatment of choroidal neovascularization (CNV) associated with pathologic myopia, presumed ocular histoplasmosis syndrome (POHS), idiopathic CNV, choroidal hemangioma, and central serous chorioretinopathy. The presence of LDL-receptor in the conjunctival pterygium vessels will allow a preferential uptake of verteporfin-LDL complex, ideal for PDT. The regression of the pterygia after PDT may greatly facilitate successful removal and prevent the need for surgical excision or re-operation.

Keywords: Pterygium • neovascularization • photodynamic therapy 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.